Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation

Drug Category : Array
Conference Category : Array
Lead Author : Mato A, et al.
Published Date : 02/12/2018
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASH-2018-U2-Pembro-Mato-Final.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top